Q-linea announces the initiation of another US ASTar evaluation
Q-linea AB (publ) (OMX: QLINEA) today announces the contract signing for an ASTar® evaluation of a large independent hospital system in the Southeastern United States.
The facility specializes in treating cancer and pediatric patients, two populations who will especially benefit from rapid antibiotic susceptibility test results. Installation is planned for late March, with training and evaluation scheduled to begin in April. Clinical implementation is anticipated in 2025.